Dendrimers as an effective nanocarrier in cardiovascular disease

Avinash Gothwal, Prashant Kesharwani, Umesh Gupta, Iliyas Khan, Mohd Cairul Iqbal Mohd Amin, Sanjeev Banerjee, Arun K. Iyer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In the last two decades, dendrimers have proven their capabilities in drug delivery, physical stabilization of the drug, solubility enhancement of the poorly soluble drugs and gene delivery. Several key features of dendrimers such as excellent control over molecular structure, nanoscopic size, availability of multiple functional groups at the periphery and narrow polydispersity index distinguish them as a superior choice over available polymers. The diversity of bio-actives loaded in dendrimers due to covalent and non-covalent interactions, such as hydrogen bonding and hydrophobic interaction contribute to the physical forces for binding of bioactives. The key advantage of drug-loaded dendrimers is the delayed and sustained-release of bioactives because of the encapsulation of the drug in the hydrophobic cavities of the dendrimer that acts as a sink to retain the drug molecules for extended duration. Because of these features researchers are particularly excited about the potential application of dendrimers as a versatile carrier for drug delivery. Collectively, this review focuses on detailed note on the delivery and improved solubility of poorly soluble anti-cardiovascular bioactives, nitric oxide (NO) donor for anti-thrombosis, gene delivery and delivery of receptor agonists for cardio-protective action of the receptors using dendrimers.

Original languageEnglish
Pages (from-to)4519-4526
Number of pages8
JournalCurrent Pharmaceutical Design
Volume21
Issue number30
Publication statusPublished - 1 Sep 2015

Fingerprint

Dendrimers
Cardiovascular Diseases
Pharmaceutical Preparations
Solubility
Drug Carriers
Nitric Oxide Donors
Hydrogen Bonding
Molecular Structure
Hydrophobic and Hydrophilic Interactions
Genes
Polymers
Thrombosis
Research Personnel

Keywords

  • Adenosine receptors
  • Cardiovascular disease
  • Dendrimer
  • Nitric oxide donor
  • Thrombosis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Gothwal, A., Kesharwani, P., Gupta, U., Khan, I., Mohd Amin, M. C. I., Banerjee, S., & Iyer, A. K. (2015). Dendrimers as an effective nanocarrier in cardiovascular disease. Current Pharmaceutical Design, 21(30), 4519-4526.

Dendrimers as an effective nanocarrier in cardiovascular disease. / Gothwal, Avinash; Kesharwani, Prashant; Gupta, Umesh; Khan, Iliyas; Mohd Amin, Mohd Cairul Iqbal; Banerjee, Sanjeev; Iyer, Arun K.

In: Current Pharmaceutical Design, Vol. 21, No. 30, 01.09.2015, p. 4519-4526.

Research output: Contribution to journalArticle

Gothwal, A, Kesharwani, P, Gupta, U, Khan, I, Mohd Amin, MCI, Banerjee, S & Iyer, AK 2015, 'Dendrimers as an effective nanocarrier in cardiovascular disease', Current Pharmaceutical Design, vol. 21, no. 30, pp. 4519-4526.
Gothwal A, Kesharwani P, Gupta U, Khan I, Mohd Amin MCI, Banerjee S et al. Dendrimers as an effective nanocarrier in cardiovascular disease. Current Pharmaceutical Design. 2015 Sep 1;21(30):4519-4526.
Gothwal, Avinash ; Kesharwani, Prashant ; Gupta, Umesh ; Khan, Iliyas ; Mohd Amin, Mohd Cairul Iqbal ; Banerjee, Sanjeev ; Iyer, Arun K. / Dendrimers as an effective nanocarrier in cardiovascular disease. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 30. pp. 4519-4526.
@article{5e5863e6748b41daa7a0cbbf8bb36181,
title = "Dendrimers as an effective nanocarrier in cardiovascular disease",
abstract = "In the last two decades, dendrimers have proven their capabilities in drug delivery, physical stabilization of the drug, solubility enhancement of the poorly soluble drugs and gene delivery. Several key features of dendrimers such as excellent control over molecular structure, nanoscopic size, availability of multiple functional groups at the periphery and narrow polydispersity index distinguish them as a superior choice over available polymers. The diversity of bio-actives loaded in dendrimers due to covalent and non-covalent interactions, such as hydrogen bonding and hydrophobic interaction contribute to the physical forces for binding of bioactives. The key advantage of drug-loaded dendrimers is the delayed and sustained-release of bioactives because of the encapsulation of the drug in the hydrophobic cavities of the dendrimer that acts as a sink to retain the drug molecules for extended duration. Because of these features researchers are particularly excited about the potential application of dendrimers as a versatile carrier for drug delivery. Collectively, this review focuses on detailed note on the delivery and improved solubility of poorly soluble anti-cardiovascular bioactives, nitric oxide (NO) donor for anti-thrombosis, gene delivery and delivery of receptor agonists for cardio-protective action of the receptors using dendrimers.",
keywords = "Adenosine receptors, Cardiovascular disease, Dendrimer, Nitric oxide donor, Thrombosis",
author = "Avinash Gothwal and Prashant Kesharwani and Umesh Gupta and Iliyas Khan and {Mohd Amin}, {Mohd Cairul Iqbal} and Sanjeev Banerjee and Iyer, {Arun K.}",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "21",
pages = "4519--4526",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "30",

}

TY - JOUR

T1 - Dendrimers as an effective nanocarrier in cardiovascular disease

AU - Gothwal, Avinash

AU - Kesharwani, Prashant

AU - Gupta, Umesh

AU - Khan, Iliyas

AU - Mohd Amin, Mohd Cairul Iqbal

AU - Banerjee, Sanjeev

AU - Iyer, Arun K.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - In the last two decades, dendrimers have proven their capabilities in drug delivery, physical stabilization of the drug, solubility enhancement of the poorly soluble drugs and gene delivery. Several key features of dendrimers such as excellent control over molecular structure, nanoscopic size, availability of multiple functional groups at the periphery and narrow polydispersity index distinguish them as a superior choice over available polymers. The diversity of bio-actives loaded in dendrimers due to covalent and non-covalent interactions, such as hydrogen bonding and hydrophobic interaction contribute to the physical forces for binding of bioactives. The key advantage of drug-loaded dendrimers is the delayed and sustained-release of bioactives because of the encapsulation of the drug in the hydrophobic cavities of the dendrimer that acts as a sink to retain the drug molecules for extended duration. Because of these features researchers are particularly excited about the potential application of dendrimers as a versatile carrier for drug delivery. Collectively, this review focuses on detailed note on the delivery and improved solubility of poorly soluble anti-cardiovascular bioactives, nitric oxide (NO) donor for anti-thrombosis, gene delivery and delivery of receptor agonists for cardio-protective action of the receptors using dendrimers.

AB - In the last two decades, dendrimers have proven their capabilities in drug delivery, physical stabilization of the drug, solubility enhancement of the poorly soluble drugs and gene delivery. Several key features of dendrimers such as excellent control over molecular structure, nanoscopic size, availability of multiple functional groups at the periphery and narrow polydispersity index distinguish them as a superior choice over available polymers. The diversity of bio-actives loaded in dendrimers due to covalent and non-covalent interactions, such as hydrogen bonding and hydrophobic interaction contribute to the physical forces for binding of bioactives. The key advantage of drug-loaded dendrimers is the delayed and sustained-release of bioactives because of the encapsulation of the drug in the hydrophobic cavities of the dendrimer that acts as a sink to retain the drug molecules for extended duration. Because of these features researchers are particularly excited about the potential application of dendrimers as a versatile carrier for drug delivery. Collectively, this review focuses on detailed note on the delivery and improved solubility of poorly soluble anti-cardiovascular bioactives, nitric oxide (NO) donor for anti-thrombosis, gene delivery and delivery of receptor agonists for cardio-protective action of the receptors using dendrimers.

KW - Adenosine receptors

KW - Cardiovascular disease

KW - Dendrimer

KW - Nitric oxide donor

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84946049739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946049739&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 4519

EP - 4526

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 30

ER -